Hep Magazine - The Hepatitis C Drug Pipeline Report: A Groundswell to Become a Sea Change

New York, NY
 – April 15, 2013 /Press Release/  –– 

Frantic competition between the major pharmaceutical players has accelerated progress on new hepatitis C virus (HCV) therapies to a breakneck speed. At the October 2012 annual meeting of the American Association for the Study of Liver Diseases (AASLD), scientists were charged with excitement over the promise of a new paradigm in hep C treatment, one they predicted would arrive within a few years and would include simplified, all-oral, interferon-free therapies with high cure rates for broad swaths of the hep C population. “Essentially there has been no drug resistance” to sofosbuvir, says Daniel Fierer, MD, an assistant professor of medicine in infectious diseases at the Icahn School of Medicine at Mount Sinai. “It’s as bulletproof a drug as you can get, and that is so rare.” Douglas Dieterich, MD, a professor of medicine at Mount Sinai, said “I think as soon as interferon leaves the treatment paradigm for hepatitis C, HIV providers are going to be treating hepatitis C in both mono- and coinfected patients.” Learn more